一心堂(002727.SZ):擬4億元在昆明市經開區投建中藥飲片產能擴建項目
格隆匯6月20日丨一心堂(002727.SZ)公佈,公司於2023年6月20日召開第六屆董事會第三次臨時會議,審議通過《關於同意公司全資子公司鴻翔中藥有限公司與昆明經濟技術開發區管理委員會簽訂項目投資合作協議的議案》,同意全資子公司鴻翔中藥有限公司(簡稱“鴻翔中藥”)與昆明經濟技術開發區管理委員會(簡稱“經開區管委會”)簽訂《項目投資合作協議》。
鴻翔中藥擬在昆明市經開區投資建設中藥飲片產能擴建項目,項目總投資4億元,新建數字化智能製造中藥飲片生產基地,建設中藥材、中藥飲片數字化物流配送中心及第三方檢驗平台業務服務中心。經開區管委會根據《中國(雲南)自由貿易試驗區昆明片區管理委員會昆明經濟技術開發區管理委員會關於印發促進產業高質量發展系列政策的通知》(昆自貿管〔2022〕1號),於2023年9月30日前按照法律法規在轄區範圍內為鴻翔中藥選址約40畝的(以實際出讓面積為準)工業用地,並在其職權範圍內協助鴻翔中藥依法辦理項目建設、經營所需的相關許可、備案等手續。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.